Disease Info Card

Hematologic Neoplasms

Information about Hematologic Neoplasms: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Hematologic Neoplasms

Most recent studies have shown that Hematologic Neoplasms shares some biological mechanisms with acute-gvh-disease, acute-leukemia, acute-lymphocytic-leukemia, chronic-lymphocytic-leukemia, dysmyelopoietic-syndromes, graft-vs-host-disease, hematological-disease, infective-disorder, leukemia, leukemia-myelocytic-acute, lymphoid-leukemia, lymphoma, lymphoma-non-hodgkin, malignant-neoplasms, malignant-paraganglionic-neoplasm, multiple-myeloma, mycoses, myeloid-leukemia, myeloid-leukemia-chronic, neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Hematologic Neoplasms, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Coagulation, Dna Methylation, Dna Repair, Drug Resistance, Immune Response, Induction Of Apoptosis, Interphase, Localization, Metaphase, Methylation, Pathogenesis, Secretion, Translation

Quite a number of genes have been found to play important roles in Hematologic Neoplasms, such as ASXL1, BCR, CD34, CD4, CSF2, CSF3, CTLA4, HLA-DQA1, IL2, IL6, JAK2, MID1, NOD2, PAFAH1B1, SF3B1, TNF, TP53, VEGFA, YWHAE. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.